GOSSAMER BIO, INC. Investing Cash Flow
GOSSAMER BIO, INC. (GOSS) reported Investing Cash Flow of $84.31 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-13
- GOSSAMER BIO, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $42.70M, a 3.23% decline year-over-year.
- GOSSAMER BIO, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $41.61M, a 88.59% increase year-over-year.
- GOSSAMER BIO, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $73.16M, a 37.47% increase year-over-year.
- GOSSAMER BIO, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was $17.01M.
- GOSSAMER BIO, INC. net cash provided by (used in) investing activities for fiscal 2025 was $156.36M, a 438.74% increase from fiscal 2024.
- GOSSAMER BIO, INC. net cash provided by (used in) investing activities for fiscal 2024 was $29.02M.
- GOSSAMER BIO, INC. net cash provided by (used in) investing activities for fiscal 2023 was -$110.97M.
- GOSSAMER BIO, INC. net cash provided by (used in) investing activities for fiscal 2022 was -$1.03M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $42.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $84.31M 10-Q · filed 2026-08-13 | $157.46M derived: sum of 3 quarters · filed 2026-08-13 | $174.48M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $41.61M 10-Q · filed 2026-05-15 | $114.76M derived: sum of 2 quarters · filed 2026-05-15 | $131.78M derived: sum of 3 quarters · filed 2026-05-15 | $175.90M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $73.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $90.17M derived: sum of 2 quarters · filed 2026-03-17 | $134.30M derived: sum of 3 quarters · filed 2026-08-13 | $156.36M 10-K · filed 2026-03-17 |
| 2025-09-30 | $17.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $61.14M derived: sum of 2 quarters · filed 2026-08-13 | $83.20M 10-Q · filed 2025-11-05 | $136.42M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $44.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $66.19M 10-Q · filed 2026-08-13 | $119.40M derived: sum of 3 quarters · filed 2026-08-13 | $92.65M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $22.06M 10-Q · filed 2026-05-15 | $75.28M derived: sum of 2 quarters · filed 2026-05-15 | $48.52M derived: sum of 3 quarters · filed 2026-05-15 | -$10.59M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $53.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $26.46M derived: sum of 2 quarters · filed 2026-03-17 | -$32.65M derived: sum of 3 quarters · filed 2026-03-17 | $29.02M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$26.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$85.87M derived: sum of 2 quarters · filed 2025-11-05 | -$24.19M 10-Q · filed 2025-11-05 | -$38.56M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-06-30 | -$59.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $2.56M 10-Q · filed 2025-08-05 | -$11.80M derived: sum of 3 quarters · filed 2026-03-17 | -$130.07M derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-03-31 | $61.67M 10-Q · filed 2025-05-15 | $47.31M derived: sum of 2 quarters · filed 2026-03-17 | -$70.95M derived: sum of 3 quarters · filed 2026-03-17 | -$58.02M derived: sum of 4 quarters · filed 2026-03-17 |
| 2023-12-31 | -$14.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$132.63M derived: sum of 2 quarters · filed 2026-03-17 | -$119.69M derived: sum of 3 quarters · filed 2026-03-17 | -$110.97M 10-K · filed 2026-03-17 |
| 2023-09-30 | -$118.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$105.33M derived: sum of 2 quarters · filed 2024-11-07 | -$96.60M 10-Q · filed 2024-11-07 | -$88.14M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-06-30 | $12.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $21.66M 10-Q · filed 2024-08-12 | $30.12M derived: sum of 3 quarters · filed 2025-03-13 | $7.52M derived: sum of 4 quarters · filed 2025-03-13 |
| 2023-03-31 | $8.72M 10-Q · filed 2024-05-07 | $17.19M derived: sum of 2 quarters · filed 2025-03-13 | -$5.41M derived: sum of 3 quarters · filed 2025-03-13 | -$733.00K derived: sum of 4 quarters · filed 2025-03-13 |
| 2022-12-31 | $8.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$14.13M derived: sum of 2 quarters · filed 2025-03-13 | -$9.46M derived: sum of 3 quarters · filed 2025-03-13 | -$1.03M 10-K · filed 2025-03-13 |
| 2022-09-30 | -$22.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$17.92M derived: sum of 2 quarters · filed 2023-11-09 | -$9.50M 10-Q · filed 2023-11-09 | $944.00K derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $4.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $13.10M 10-Q · filed 2023-08-08 | $23.54M derived: sum of 3 quarters · filed 2024-03-05 | -$66.22M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $8.42M 10-Q · filed 2023-05-09 | $18.86M derived: sum of 2 quarters · filed 2024-03-05 | -$70.90M derived: sum of 3 quarters · filed 2024-03-05 | -$120.97M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $10.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$79.32M derived: sum of 2 quarters · filed 2024-03-05 | -$129.40M derived: sum of 3 quarters · filed 2024-03-05 | -$117.43M 10-K · filed 2024-03-05 |
| 2021-09-30 | -$89.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$139.84M derived: sum of 2 quarters · filed 2022-11-03 | -$127.87M 10-Q · filed 2022-11-03 | -$66.77M derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-06-30 | -$50.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$38.11M 10-Q · filed 2022-08-09 | $22.99M derived: sum of 3 quarters · filed 2023-03-17 | $42.95M derived: sum of 4 quarters · filed 2023-03-17 |
| 2021-03-31 | $11.97M 10-Q · filed 2022-05-10 | $73.07M derived: sum of 2 quarters · filed 2023-03-17 | $93.03M derived: sum of 3 quarters · filed 2023-03-17 | $199.27M derived: sum of 4 quarters · filed 2023-03-17 |
| 2020-12-31 | $61.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $81.06M derived: sum of 2 quarters · filed 2023-03-17 | $187.30M derived: sum of 3 quarters · filed 2023-03-17 | $215.34M 10-K · filed 2023-03-17 |
| 2020-09-30 | $19.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $126.20M derived: sum of 2 quarters · filed 2021-11-08 | $154.24M 10-Q · filed 2021-11-08 | $201.18M derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-06-30 | $106.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $134.28M 10-Q · filed 2021-08-09 | $181.22M derived: sum of 3 quarters · filed 2022-03-03 | $199.16M derived: sum of 4 quarters · filed 2022-03-03 |
| 2020-03-31 | $28.04M 10-Q · filed 2021-05-06 | $74.97M derived: sum of 2 quarters · filed 2022-03-03 | $92.92M derived: sum of 3 quarters · filed 2022-03-03 | $79.04M derived: sum of 4 quarters · filed 2022-03-03 |
| 2019-12-31 | $46.93M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $64.88M derived: sum of 2 quarters · filed 2022-03-03 | $51.00M derived: sum of 3 quarters · filed 2022-03-03 | -$147.14M 10-K · filed 2022-03-03 |
| 2019-09-30 | $17.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | $4.07M derived: sum of 2 quarters · filed 2020-11-10 | -$194.08M 10-Q · filed 2020-11-10 | -$202.76M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | -$13.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | -$212.03M 10-Q · filed 2020-08-11 | -$220.71M derived: sum of 3 quarters · filed 2021-02-26 | -$325.82M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | -$198.14M 10-Q · filed 2020-05-12 | -$206.82M derived: sum of 2 quarters · filed 2021-02-26 | -$311.94M derived: sum of 3 quarters · filed 2021-02-26 | -$353.52M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | -$8.68M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | -$113.80M derived: sum of 2 quarters · filed 2021-02-26 | -$155.38M derived: sum of 3 quarters · filed 2021-02-26 | -$144.71M 10-K · filed 2021-02-26 |
| 2018-09-30 | -$105.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | -$146.69M derived: sum of 2 quarters · filed 2019-11-12 | -$136.03M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | -$41.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$30.91M 10-Q · filed 2019-08-08 | ||
| 2018-03-31 | $10.66M 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |